Introduction
============

Leishmaniasis is a vector-borne disease which is endemic in 98 countries worldwide \[[@r1]\]. It is caused by protozoan parasites of the genus *Leishmania*, which are transmitted by female sand flies of the genera *Lutzomyia* and *Phlebotomus*. Many infected individuals never develop symptoms, but those who do can exhibit various disease manifestations \[[@r2]\]. Visceral leishmaniasis (VL) or kala-azar is the severe form, whereby parasites infect internal organs and the bone marrow, a lethal condition if left untreated. Other disease types are restricted to the skin (cutaneous leishmaniasis, CL) or the mucosae of the nose and mouth (mucosal leishmaniasis, ML). Finally, a particular cutaneous disease sometimes develops in cured VL patients: post kala-azar dermal leishmaniasis (PKDL). Typically, VL is caused by two species: *Leishmania donovani* and *Leishmania infantum*. The latter can also cause CL, as can all other pathogenic species. Some particular species (e.g. *L. braziliensis* and *L. aethiopica*) can lead to overt ML.

As many as 20 different *Leishmania* species are able to infect humans, and globally there are over 1 million new disease cases per annum \[[@r1],[@r3]\]. Leishmaniasis is endemic in southern Europe, and in other European countries cases are diagnosed in travellers who have visited affected areas both within the continent and beyond. Although treatment in practice is often guided only by clinical presentation and patient history, in some cases determination of the aetiological subgenus, species complex or species is recommended for providing optimal treatment \[[@r2],[@r4],[@r5]\]. For example, a patient returning from South America with CL might be infected with *Leishmania braziliensis*, which necessitates systemic drug therapy and counselling about the risk of developing mucosal leishmaniasis in the future. The same patient could also be infected with *Leishmania mexicana*, which is managed by less intensive treatment and which is not associated with mucosal disease \[[@r6]\]. Determining the infecting species and its probable source permits selection of the correct drug, route of administration (intralesional, oral systemic, or parenteral) and duration \[[@r7]\].

Unfortunately, for CL it is impossible to predict the species responsible for an ulcerating lesion clinically, and the morphology of amastigotes does not differ between species. When the geographical origin of infection is known, for instance when a patient in an endemic region is treated at a local hospital, the species can be guessed often from the known local epidemiology, as species distribution follows a geographical pattern \[[@r8]\]. However, especially in infectious disease clinics that treat patients who have stayed in various endemic countries, the geographic origin of infections may be unknown. For instance, people residing in Europe who have travelled outside Europe may come from, or have also visited, *Leishmania*-endemic areas within Europe, especially the Mediterranean basin. Even when the location of infection is known, several species can co-circulate in a given endemic area, in which case the species can only be determined by laboratory tests. Culture and subsequent isoenzyme analysis is time consuming and available in very few specialised centres, so it is impractical as a front-line diagnostic test in clinical laboratories. Hence, well-performed reliable molecular methods are necessary for species identification.

Several *Leishmania* typing methods have been published (reviewed in \[[@r9]\]), and as a result each laboratory uses its own preferred assay. The most popular assays nowadays are those that can be applied directly to clinical samples, thereby circumventing the need for parasite isolation and culture. However, few tests have been standardised, and no commercial kits are currently available. As a result, clinical and epidemiological studies make use of various techniques, and in patient management other methods are often deployed. In this study we compare the typing performance in 16 clinical laboratories across Europe, which use a variety of methods for species discrimination.

Methods
=======

Participants and reference methods
----------------------------------

Twenty one *Leishmania* isolates were typed by 16 laboratories in 12 countries in 2014. [Table 1](#t1){ref-type="table"} lists the parasite strains that were used in this study, along with the reference method for species identification. Strains identified with a Laboratoire d\'Ecologie Médicale (LEM) code were provided by the Centre National de Référence des Leishmanioses in Montpellier, France, which assigns LEM codes to each cryopreserved culture, while the remaining three strains were provided by the Institute of Tropical Medicine in Antwerp, Belgium.

###### Strains used, study comparing *Leishmania* typing results in 16 European clinical laboratories, 2014

  Strain (WHO code)      Culture name CNRL^a^   Species^b^                             Reference typing method^c^
  ---------------------- ---------------------- -------------------------------------- ----------------------------
  MHOM/ET/83/130--83     LEM1118                *Leishmania aethiopica*                MLEE, MLSA
  MHOM/GF/2002/LAV003    LEM4351                *L. amazonensis*                       MLEE, MLSA
  MHOM/VE/76/JAP78       LEM0391                *L. amazonensis*                       MLEE, MLSA
  MHOM/BR/75/M2903b      LEM0396                *L. braziliensis*                      MLEE, MLSA
  MHOM/PE/83/STI139      LEM0781                *L. braziliensis*                      MLEE, MLSA
  MHOM/BO/2001/CUM555    NA                     *L. braziliensis* outlier^d^           AFLP \[[@r12]\], WGS, MLSA
  MHOM/IN/\--/LRC-L51    LEM1070                *L. donovani*                          MLEE, MLSA
  MHOM/KE/55/LRC-L53     LEM0707                *L. donovani*                          MLEE, MLSA
  MHOM/GF/86/LEM1034     LEM1034                *L. guyanensis*                        MLEE, MLSA
  MHOM/FR/78/LEM75       LEM0075                *L. infantum*                          MLEE, MLSA
  MCUN/BR/85/M9342       LEM2229                *L. lainsoni*                          MLEE, MLSA
  MHOM/IQ/86/CRE1        LEM0858                *L. major*                             MLEE, MLSA
  MHOM/BZ/82/BEL21       LEM0695                *L. mexicana*                          MLEE, MLSA
  MHOM/EC/87/EC103-CL8   LEM1554                *L. mexicana*                          MLEE, MLSA
  MDAS/BR/79/M5533       LEM2204                *L. naiffi*                            MLEE, MLSA
  MHOM/CO/86/UA126       LEM1047                *L. panamensis*                        MLEE, MLSA
  MHOM/CO/88/UA264       LEM1492                *L. panamensis*                        MLEE, MLSA
  MHOM/CO/88/UA316       LEM1505                *L. panamensis* / *L. guyanensis*^e^   MLEE, MLSA
  MHOM/PE/90/HB86        NA                     *L. peruviana*                         AFLP \[[@r12]\], WGS, MLSA
  MHOM/PE/90/LCA08       NA                     *L. peruviana*                         AFLP \[[@r12]\], WGS, MLSA
  MHOM/IL/80/SINGER      LEM0617                *L. tropica*                           MLEE, MLSA

AFLP: amplified fragment length polymorphism; CNRL: Centre National de Référence des Leishmanioses (Montpellier, France); NA: not applicable; MLEE: multilocus enzyme electrophoresis; MLSA: multilocus sequence analysis; WGS: whole genome sequencing; WHO: World Health Organization.

^a^ Identification in the Montpellier cryobank (Centre National de Référence des Leishmanioses).

^b^ For the taxonomic position of each species (subgenus and species complex), please refer to Figure 2.

^c^ Reference method used to determine the species of each isolate. MLEE \[[@r10]\]; MLSA based on seven genes \[[@r11]\]; AFLP analysis \[[@r12]\]; WGS (unpublished results).

^d^ Group of distinct *Leishmania braziliensis* strains \[[@r9],[@r12]\], also called *L. braziliensis* type 2 \[[@r15]\] or atypical *L. braziliensis* \[[@r18]\].

^e^ This strain was typed as *L. panamensis* by MLSA, and as *L. guyanensis* by MLEE.

Four highly informative reference methods were used: multilocus enzyme electrophoresis (MLEE \[[@r10]\]), multilocus sequence analysis (MLSA \[[@r11]\], GenBank sequence accession numbers in [Table 2](#t2){ref-type="table"}), genome-wide amplified fragment length polymorphism (AFLP) analysis \[[@r12]\], and whole genome sequencing (unpublished results).

###### GenBank sequence accession numbers from MLSA and *hsp70,* for sequences used in study comparing *Leishmania* typing results in 16 European clinical laboratories, 2014

  WHO CODE               LEM    MLSA locus   *hsp70*                                                           
  ---------------------- ------ ------------ ---------- ---------- ---------- ---------- ---------- ---------- ----------
  MCUN/BR/85/M9342       2229   KT959002     KT959017   KT959032   KT959047   KT959062   KT959077   KT959092   LN907839
  MDAS/BR/79/M5533       2204   KT959001     KT959016   KT959031   KT959046   KT959061   KT959076   KT959091   FR872767
  MHOM/BO/2001/CUM555    NA     KT959006     KT959021   KT959036   KT959051   KT959066   KT959081   KT959096   FR872760
  MHOM/BR/75/M2903b      396    KT958993     KT959008   KT959023   KT959038   KT959053   KT959068   KT959083   LN907832
  MHOM/BZ/82/BEL21       695    KT958994     KT959009   KT959024   KT959039   KT959054   KT959069   KT959084   LN907841
  MHOM/CO/86/UA126       1047   KT958997     KT959012   KT959027   KT959042   KT959057   KT959072   KT959087   LN907843
  MHOM/CO/88/UA264       1492   KT958998     KT959013   KT959028   KT959043   KT959058   KT959073   KT959088   LN907844
  MHOM/CO/88/UA316       1505   KT958999     KT959014   KT959029   KT959044   KT959059   KT959074   KT959089   LN907837
  MHOM/EC/87/EC103-CL8   1554   KT959000     KT959015   KT959030   KT959045   KT959060   KT959075   KT959090   LN907842
  MHOM/ET/83/130--83     1118   KC159315     KC159537   KC159093   KC159759   KC158871   KC159981   KC158649   LN907830
  MHOM/FR/78/LEM75       75     KC159255     KC159477   KC159033   KC159699   KC158811   KC159921   KC158589   LN907838
  MHOM/GF/2002/LAV003    4351   KT959003     KT959018   KT959033   KT959048   KT959063   KT959078   KT959093   LN907831
  MHOM/GF/86/LEM1034     1034   KT958996     KT959011   KT959026   KT959041   KT959056   KT959071   KT959086   LN907836
  MHOM/IL/80/SINGER      617    KC159287     KC159509   KC159065   KC159731   KC158843   KC159953   KC158621   LN907846
  MHOM/IN/\--/LRC-L51    1070   KC159313     KC159535   KC159091   KC159757   KC158869   KC159979   KC158647   LN907834
  MHOM/IQ/86/CRE1        858    KC159299     KC159521   KC159077   KC159743   KC158855   KC159965   KC158633   LN907840
  MHOM/KE/55/LRC-L53     707    KC159294     KC159516   KC159072   KC159738   KC158850   KC159960   KC158628   LN907835
  MHOM/PE/1990/HB86      NA     KT959004     KT959019   KT959034   KT959049   KT959064   KT959079   KT959094   LN907845
  MHOM/PE/1990/LCA08     NA     KT959005     KT959020   KT959035   KT959050   KT959065   KT959080   KT959095   EU599089
  MHOM/PE/83/STI139      781    KT958995     KT959010   KT959025   KT959040   KT959055   KT959070   KT959085   LN907833
  MHOM/VE/76/JAP78       391    KT958992     KT959007   KT959022   KT959037   KT959052   KT959067   KT959082   EU599092

LEM: Laboratoire d\'Ecologie Médicale; MLSA: multilocus sequence analysis; *hsp70*: heat-shock protein 70 gene; NA: not applicable; WHO: World Health Organization.

DNA was extracted from parasite cultures using either the DNeasy Blood and Tissue Kit or QIAamp DNA Mini Kit (Qiagen, [www.qiagen.com](http://www.qiagen.com)), and the concentration was measured spectrophotometrically. The 21 DNAs were randomised at the United Kingdom (UK) National External Quality Assessment Service for Parasitology (UKNEQAS, London, UK), and every study participant received a blind panel containing 50 µl of a 10 ng/µl DNA solution. The participating laboratories are listed in [Table 3](#t3){ref-type="table"}.

###### Participants in study comparing *Leishmania* typing results in 16 European clinical laboratories, 2014

  Institute                                                   City          Country
  ----------------------------------------------------------- ------------- -----------------
  Institute of Tropical Medicine Antwerp^a^                   Antwerp       Belgium
  Centre National de Référence des Leishmanioses^a,b^         Montpellier   France
  Centre Hospitalier Universitaire de Rennes                  Rennes        France
  Charité-Universitätsmedizin Berlin                          Berlin        Germany
  Hebrew University-Hadassah Medical Centre                   Jerusalem     Israel
  Istituto Superiore di Sanità                                Rome          Italy
  National Institute for Infectious Diseases L. Spallanzani   Rome          Italy
  Instituto de Higiene e Medicina Tropical                    Lisbon        Portugal
  Instituto de Salud Carlos III                               Majadahonda   Spain
  The Public Health Agency of Sweden                          Stockholm     Sweden
  Swiss Tropical and Public Health Institute^a^               Basel         Switzerland
  Institute of Parasitology                                   Zürich        Switzerland
  Academic Medical Center, University of Amsterdam            Amsterdam     The Netherlands
  National Institute for Public Health and the Environment    Bilthoven     The Netherlands
  St. Elisabeth Hospital                                      Tilburg       The Netherlands
  Ege University Medical School                               Izmir         Turkey
  Hospital for Tropical Diseases                              London        United Kingdom

Institutes are listed in alphabetical order based on country and city.

^a^ These laboratories provided parasite cultures and DNA.

^b^ This laboratory applied one of the reference methods (MLSA) and did not participate in the comparative study of typing outcomes.

After performing the respective routine typing technology, each laboratory reported its results to UKNEQAS, who forwarded these along with the randomised code in one batch to the Institute of Tropical Medicine in Antwerp for analysis. Some participants used the term '*L. braziliensis* complex' when referring to the *L.* (*Viannia*) subgenus, and where needed the reported results were adjusted. The results after these adjustments are presented in this analysis.

Genome targets for typing
-------------------------

The 16 laboratories used a total of five genome targets for typing ([Table 4](#t4){ref-type="table"}): the internal transcribed spacer 1 of the rDNA array (ITS1), the mini-exon, kinetoplast minicircle DNA (kDNA), the heat-shock protein 70 gene (*hsp70*), and a repetitive DNA sequence. One laboratory reported two sets of result from two different targets, which are treated in the analysis as if they were from separate laboratories, which is why the results section describes 17 instead of 16 outcomes. The targets were analysed with PCR, generally followed by sequencing or restriction fragment length polymorphism (RFLP) analysis, as shown in [Table 4](#t4){ref-type="table"} and Figure 1. Four laboratories used in-house sequencing, while five others used the service of an external sequencing facility. PCRs based on kDNA did not require post-PCR manipulations other than gel analysis.

###### Typing methods used in study comparing *Leishmania* typing results in 16 European clinical laboratories, 2014

  Genomic locus / gene   Analysis method                Number of laboratories^a^
  ---------------------- ------------------------------ ---------------------------
  ITS1                   RFLP \[[@r13],[@r14]\]         7
                         Sequencing \[[@r15]\]          4
  *hsp70*                Sequencing \[[@r15],[@r16]\]   5
                         RFLP \[[@r17]\]                2
  Mini-exon              Sequencing \[[@r19]-[@r21]\]   3
  kDNA minicircles       RFLP \[[@r24],[@r25]\]         1
                         Specific PCR \[[@r23]\]        1
  Repetitive DNA         RFLP \[[@r26]\]                1

ITS: internal transcribed spacer; *hsp70*: heat-shock protein 70 gene; kDNA: kinetoplast minicircle DNA; RFLP: restriction fragment length polymorphism.

^a^ The total number is higher than the 16 participating laboratories, because several laboratories used different methods in parallel.

Figure 1 indicates for each laboratory individually which method or methods were used, but not all samples were necessarily analysed with each method. Of the 16 laboratories, 11 used the ITS1 target, either applying RFLP (n=7) or sequencing (n=4). All of them based their analysis on the fragment described in \[[@r13]\], except for laboratory L which used a larger region also including ITS2 \[[@r14]\]. Five laboratories based typing on *hsp70*: four (A-D) used sequencing of the F fragment described in \[[@r15]-[@r17]\], while one (E) used the N fragment. Two laboratories (F and G) analysed this gene with RFLP \[[@r17],[@r18]\]. Three laboratories used sequence analysis of the mini-exon gene: laboratory O \[[@r19],[@r20]\], laboratory P \[[@r21]\], and laboratory Q \[[@r22]\]. Two laboratories based typing partly on kDNA: laboratory K \[[@r23]\], and laboratory L \[[@r24],[@r25]\]. Finally, laboratory J complemented ITS1-RFLP with RFLP analysis of a repetitive DNA sequence \[[@r26]\].

Grading of results
------------------

Each individual result was graded as follows. The best ranking was given to reported species agreeing with the reference methods, whereby *L. garnhami* was considered a synonym of *L. amazonensis* \[[@r27]\]. Results reporting MHOM/BO/2001/CUM555 as *L. braziliensis* were considered correct. Although this strain belongs to a group of clearly distinguishable outliers ([Table 1](#t1){ref-type="table"}), it has so far not been described as a separate species. Next were identifications that reported the species complex rather than the actual species (see Figure 2), and were in agreement with the reference methods. The lowest ranking of correct results was given to those identifying the subgenus, i.e. *L.* (*Viannia*) or *L.* (*Leishmania*), without specification of species or species complex. Identification errors were graded at two levels. First, some laboratories reported a species within the correct complex, but identified the wrong species within that complex. Second, some isolates were placed in an erroneous species complex altogether. A peculiar case was presented by strain MHOM/CO/88/UA316, which was *L. guyanensis* based on MLEE, but *L. panamensis* based on MLSA ([Table 1](#t1){ref-type="table"}). For this strain, all results reporting either *L. guyanensis* or *L. panamensis* were considered to have identified the correct species complex.

In a next level of the analysis, the cause of erroneous typings was sought by means of in-depth assessment of the methods. The reasons for different identification outcomes of laboratories using the same methods were also identified. Sequences from laboratories that based their typing on the same genes were compared by alignment in the software package MEGA5 \[[@r28]\].

Results
=======

Results from all analyses are summarised in [Figure 1](#f1){ref-type="fig"}, details are available from \[[@r29]\]. One laboratory reported two sets of results because identification based on *hsp70* sequences was sometimes in conflict with those of ITS1 sequencing. These results are listed separately from laboratories E and M respectively, which brings the number of reported result sets from the 16 laboratories to 17. Most laboratories succeeded in typing all 21 samples, but in some cases results were reported for 20/21 isolates only (laboratories D, K, L, M). The total number of erroneous identifications amounted to 30, with 23 of these being classified in an incorrect species complex. On a total of 353 results, these represent 8.5% and 6.5% respectively. The correct species was identified in 211 typing results (60%), while 58 (16%) identified the correct species complex, and 54 (15%) the correct subgenus. Eight laboratories made no incorrect assignments, while the laboratory with most errors (laboratory J) misidentified 10 out of 21 samples, seven of which were placed in the wrong species complex. Laboratories relying only on kDNA and ITS1 more frequently reported results to the subgenus level, while laboratories using the mini-exon or *hsp70* often succeeded in obtaining identification either to the species or complex level.

![Typing results obtained in study comparing *Leishmania* typing results in 16 European clinical laboratories, 2014](eurosurv-21-30418-f1){#f1}

[Figure 2](#f2){ref-type="fig"} depicts the typing results for each strain, irrespective of the methods used. The only two species that were correctly identified with all methods were *L. tropica* and *L. major*. Strains from the *L.* (*Leishmania*) subgenus were identified to either the species or complex level by all laboratories. This was in contrast to the 11 strains from the *L.* (*Viannia*) subgenus, each of which was typed by four to six laboratories only to the subgenus level. The error rate for both subgenera was comparable: 8.4% (14/167) for *L.* (*Leishmania*) and 8.6% (16/186) for *L.* (*Viannia*). The error rate in Old World strains was lower than for strains of the New World: 5.9% (6/102) and 9.6% (24/251) respectively.

![Typing results for each of the 21 strains included in study comparing *Leishmania* typing results in 16 European clinical laboratories, 2014](eurosurv-21-30418-f2){#f2}

When comparing the *hsp70* sequences provided by four laboratories (A-D), there were marked differences in sequence quality. Three laboratories (A, B, C) succeeded in sequencing the entire or nearly entire fragment F \[[@r17]\], with few or no sequence ambiguities. The sequence sets of two laboratories (A and C) contained one insertion and one deletion relative to the other data, indicating sequence mistakes as the gene shows no size variation \[[@r15],[@r16]\]. In contrast, the quality of the fragment F sequences from one laboratory (D) was considerably lower. Sequences were largely incomplete at their 5' end and to a lesser extent at their 3' terminus, and numerous insertions, deletions, and unresolved nucleotides (nt) were present. One laboratory (E) sequenced only the N fragment \[[@r17]\], but base calling quality was poor in the 40 terminal 3' nt. The consensus *hsp70* sequences were deposited in GenBank ([Table 2](#t2){ref-type="table"}).

Three laboratories (M, N, O) determined the ITS1 sequence of all isolates, while one laboratory (P) sequenced only MHOM/GF/2002/LAV003. The sequences of two laboratories (N and P) covered the entire amplified PCR product, while some of two others (O and M) were incomplete at the termini. Apart from some insertions in the sequences of one laboratory (N) and occasional unresolved nt in those of another (O), the sequences were identical, except for isolate MHOM/CO/88/UA316. Here, up to 9 nt differences were present in a 120 nt stretch.

Three laboratories (O, P, Q) determined the mini-exon sequences. For some strains the sequences of these laboratories were nearly identical, but for others large size differences of the determined fragment were seen, and deletions and nt identity discrepancies were observed. Also, many nt were not fully resolved.

Discussion
==========

As a general observation, eight laboratories who participated in this comparison typing performance made no errors, and often laboratories using the same typing marker reported different results ([Figure 1](#f1){ref-type="fig"}). Two of the 'error-free' laboratories obtained the highest typing accuracy, with 20 out of 21 strains typed to the species level, and strain MHOM/CO/88/UA316 at the complex level. Using our reference methods MLSA and MLEE ([Table 1](#t1){ref-type="table"}), the latter species could not be classified unequivocally, and hence results placing it in the *L. guyanensis* complex were regarded as correct. These two laboratories (A and B) based their typing on *hsp70* gene sequencing, which was identified as one of the typing methods with the highest resolution in other comparative studies \[[@r9],[@r15]\]. One other laboratory (C) also made use of this method, but typed several strains only to the complex level. Even though the *hsp70* gene often permits distinction between closely related species, separating them is not always straight-forward. For instance, some MLEE-defined *L. guyanensis* have the same sequence as *L. panamensis* \[[@r16]\]. Because identifying the exact species within a given complex can therefore be difficult, one laboratory (C) decided to identify the species complex rather than the exact species in case of doubt. Apparently the low sequence quality obtained by one of the participants (D) had no adverse effects on the results, probably because species-specific nt identities were not affected. The sequence quality was not influenced by the use of in-house vs external sequencing services.

One laboratory (E) reported four mistakes based on *hsp70* sequences. As opposed to laboratories A-D, the analysis was based on a smaller part of the gene, fragment N \[[@r17]\], which is not suited for typing all species \[[@r15]\]. Nevertheless, several of these species were called based on a BLAST search in GenBank \[<https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch>\], from which the first listed species was regarded as the final result, regardless of identical similarity scores obtained from other species. In this process some species were by chance determined correctly, while others were erroneously identified. This stresses the importance of correctly interpreting output lists generated by BLAST, because different species can have the same similarity score when the marker is too conservative for discriminating between them. To avoid such errors the species complex rather than the species itself should have been reported. On one occasion, the applied methodology even identified an erroneous complex, i.e. MHOM/ET/83/130--83 was typed as *L. donovani* instead of *L. aethiopica*, based on an erroneous annotation in GenBank. Indeed, several GenBank entries of \[[@r30]\] were wrongfully submitted as *L. donovani*, while they derived in fact from other species \[[@r16]\]. This illustrates the importance of critically evaluating BLAST results, and underscores the importance of an agreed reference panel of sequences from trustworthy laboratories and knowledge of the limitations of a typing marker.

The same laboratory E reported a second results set based on ITS1 sequence analysis, listed under laboratory M in [Figure 1](#f1){ref-type="fig"}. Again, BLAST analysis was applied, and even though ITS1 is not suitable for discriminating *L. braziliensis* and *L. guyanensis* complex species \[[@r15]\], several species were reported. Except for one misclassified *L. braziliensis* outlier strain ([Figure 2](#f2){ref-type="fig"}), species were correctly assigned by laboratory M. However, in several cases also other species showed the same similarity scores, and hence there was no ground for naming the exact species. In contrast, another laboratory (N), which also used ITS1 sequence analysis, reported *L.* (*Viannia*) strains at subgenus level with no further attempt to determine the complex or species. Thereby they respected the limitations of ITS1, although some *L.* (*Viannia*) complexes could have been identified based on their data.

The majority of study participants that used ITS1 did not sequence the target, but relied on RFLP analysis. Laboratories basing their results on this method reported some typical errors: *L. tropica* was mixed up with *L. aethiopica*; the *L. donovani* complex was confused with *L. mexicana*; unsuccessful attempts were made to separate *L. infantum* from *L. donovani*; and on one occasion *L. amazonensis* was identified as *L. major*. When digesting the PCR products with the popular enzyme *Hae*III, sufficient gel resolution is needed in order not to mix up the aforementioned species, as their RFLP fragments are similar in size. In addition, contrary to what was originally published \[[@r13]\], *L. infantum* cannot be distinguished from *L. donovani* \[[@r9]\] and therefore ITS1 can only type to the *L. donovani* complex, without further specification.

Two laboratories (F and G) complemented ITS-RFLP with *hsp70*-RFLP, and both mistook *L. naiffi* for *L. braziliensis*. This is a result of identical patterns generated from *L. naiffi* and many *L. braziliensis* strains with restriction endonucleases *Hae*III and *Rsa*I. The mistake could have been avoided by using the appropriate enzyme *Sdu*I \[[@r18]\].

Only one laboratory (J) made use of a repetitive DNA sequence originally described in \[[@r31]\]. In combination with ITS1, 10 out of the 21 typings were incorrect, whereby seven strains were assigned to the wrong complex. Of the 10 mistakes, nine were made in the *L.* (*Viannia*) subgenus, while the remaining error was due to the unsuccessful separation of *L. infantum* from *L. donovani*. ITS1-RFLP is not suitable for discriminating these species, and the repetitive sequence RFLP was designed for typing Old World strains, where only the *L.* (*Leishmania*) subgenus is encountered. Such mistakes once more underline the importance of knowing the limits of the typing marker chosen.

Kinetoplast DNA is primarily a useful marker to discriminate the two *Leishmania* subgenera, but is less suited for typing to the actual species level (reviewed in \[[@r9]\]). In combination with the fact that also ITS1-RFLP does not discriminate many *L.* (*Viannia*) species, the two laboratories (K and L) using these methods reported typing mostly to the subgenus or species complex level. One of them (K) had a particularly high error rate (6/20) using these markers, probably related to the previously mentioned gel resolution problems and separation of *L. infantum* from *L. donovani* with ITS1-RFLP. In addition the laboratory used '*L. braziliensis* complex / *L. guyanensis* complex' as a synonym for *L.* (*Viannia*), while two strains were *L. naiffi* and *L. lainsoni*.

With the mini-exon sequences, only two mistakes were reported. One laboratory (O) identified *L. mexicana* strain MHOM/EC/87/EC103-CL8 as *L. donovani*, but after disclosing the results realised a mistake in reporting, as their analysis actually did show the correct species. In a comparative analysis of four markers \[[@r15]\], the mini-exon together with *hsp70* were identified as the most discriminative markers worldwide, which is confirmed by the results presented here. Some species within the complexes can, however, not be resolved based on the mini-exon, as also reflected in the current analysis, where often complexes rather than species were identified.

When looking at the typing results for each of the 21 strains ([Figure 2](#f2){ref-type="fig"}), it is apparent that strains of the *L.* (*Viannia*) subgenus were more often typed to the subgenus level, while those of the *L.* (*Leishmania*) subgenus were more often reported at the species level. Given that ITS1 was the most popular marker, this is a logical result in view of the poor discrimination of *L.* (*Viannia*) species by ITS1. Also the fact that for Old World strains 5.9% of typings were erroneous, in comparison to 9.6% New World strains, relates to the use of methods that are tailored to Old World strains. Only two strains were identified to the species level by all laboratories and all methods: MHOM/IL/80/SINGER (*L. tropica*) and MHOM/IQ/86/CRE1 (*L. major*). The results show that several laboratories are currently unable to discriminate *L.* (*Viannia*) species, which is partly explained by the participation in the study of six groups that are situated in a European country where *Leishmania* is actively transmitted. Hence, they mainly diagnose patients infected by endemic species, and use methods primarily tailored to species in the Old World. On the contrary, the remaining laboratories are dealing only with imported leishmaniasis cases, which can originate from anywhere in the world, and for which the origin of infection is sometimes unknown. This forces them to apply assays that are able to identify species from everywhere around the globe.

With regard to nomenclature, there is an evident need for standardisation. When the first results were reported, several laboratories used the term '*L. braziliensis* complex' to refer to *L.* (*Viannia*). For many years these have been synonyms, but current literature restricts this term to *L. braziliensis* and *L. peruviana* \[[@r27]\]. Another confusion can arise from the fact that each complex bears the name of one of its constituent species. For instance, a typing outcome reported as '*L. guyanensis*' has to be clearly distinguished from '*L. guyanensis* complex'. Even though this particular problem did not seem to occur in our analysis, one could easily envision such occurrence. One laboratory (K) reported several results as '*L. braziliensis* complex / *L. guyanensis* complex' for referring to *L.* (*Viannia*), but with this term *L. naiffi* and *L. lainsoni* were excluded.

Finally, the particular case of strain MHOM/CO/88/UA316 draws attention to problems in species definitions, as this strain was typed as *L. guyanensis* with MLEE, but as *L. panamensis* with MLSA ([Table 1](#t1){ref-type="table"}). Reported correct results for this strain were either *L. guyanensis* complex, *L. guyanensis*, or *L. panamensis*, but this was irrespective of the method or target used \[[@r29]\]. Such occasional dubious results are unavoidable when dealing with closely related species, in particular *L. guyanensis-L. panamensis*; *L. braziliensis-L. peruviana*; *L. mexicana-L. amazonensis*; and *L. donovani-L. infantum* \[[@r9]\]. Also newly documented parasite species such as *L. martiniquensis* \[[@r32]\] and *L. waltoni* \[[@r33]\], and variants as the *L. braziliensis* outlier \[[@r9],[@r12],[@r15],[@r18]\] further complicate the interpretation of typing results. It is therefore of utmost importance that species identification is performed with a well-documented standard operating procedure (SOP), clearly describing not only experimental procedures, but also in detail how results should be analysed, interpreted, and reported.

The current study was performed on cultured parasite isolates, so all participants received a high amount of pure parasite DNA. Yet, 8.5% errors were seen, and in four cases no result was obtained. When dealing with patient material, the amount of parasite DNA is much lower, and vastly exceeded by human DNA. As the current study did not assess the sensitivity of the methods used, it is expected that typing success based on clinical samples will be considerably lower. In view of the fact that only recognised reference laboratories participated in this study, there is a clear need for optimisation. On the other hand, in many clinical settings the suspected origin of infection can help in interpretation of typing outcomes, thereby possibly lowering the error rate.

Conclusions
===========

There is considerable room for improvement of current *Leishmania* typing strategies, and inter-laboratory comparisons such as the one we conducted can contribute to enhance typing quality. Whichever the clinical need for determining the subgenus, complex, or species, and whichever the technology used in a particular setting, typing should be based on a well-defined and validated SOP designed by an expert in *Leishmania* taxonomy. This SOP should cover not only testing, but also analysis and interpretation procedures, and a clear description of how species should be named and reported, taking into account the limitations of each marker and technique, and the problem of resolving closely related species or occasional inter-species hybrids. Validation should be performed on a sufficient amount of reference isolates from various geographic origins to cover each species' variability. When using sequencing, sequence errors should be avoided, and a well-validated sequence reference set is recommended over BLAST analysis using GenBank, which lacks quality control. In cases where treatment is species- or complex-dependent, clinicians should be made aware of the limitations of the technology used whenever results are reported, especially when closely related species are involved. The use of real-time PCR assays developed for specific complexes or species could speed up typing and facilitate interpretation of results, but currently no globally applicable methods are available. As previously recommended \[[@r15]\] and also apparent from this analysis, *hsp70* and the mini-exon currently offer the best *Leishmania* typing tools world-wide, and the use of ITS1 should be restricted to the Old World. Setting up similar evaluations outside Europe, in institutes in endemic as well as non-endemic countries, would shed additional light on the quality of *Leishmania* typing across the globe.
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